Speaker: Francesca Fumagalli, Neurologist, Pediatric Immunohematology Unit and Department of Neurology San Raffaele Hospital, Milan (Italy)

Learning Objectives: (1) An overview of current treatment options available for patients with MLD (2) Exploring the development of emerging therapies and treatment options (3) The importance of early diagnosis and the early start of treatments for both established and emerging therapies

Metachromatic Leukodystrophy (MLD) is a rare hereditary disease characterized by the accumulation of fats called sulfatides. This causes the destruction of the protective fatty layer (myelin sheath) surrounding the nerves in both the central nervous system and the peripheral nervous system, ultimately affecting intellectual and motor function. Early-onset clinical manifestations are often overlooked or confused with other conditions causing confusion among non-trained HCPs at first contact, resulting in misdiagnosis, wrong referral routes and delays in the early start of treatment. Delays in starting treatment have significant consequences on the conditions’ development, and the patient’s health and quality of life. This delay in referral and treatment must be overcome.

The webinar is free to view and a certificate of attendance will be provided by the EIP Institute for those who attend online or watch the video.